Figure 7

Effect of neuromodulators after blocking N-type VGCC. A, Results of one channel applying each drug sequentially (filled circle: LII/III, open circle: LV/VI): ω-Ctx-GVIA (1 μM) for 15 min, 1S,3R–ACPD (200 μM) for 10 min, (R)-Baclofen (5 μM) for 5 min, 2-CA (5 μM) for 5 min and Cch (10 μM) for 10 min. B, Averaged data (n = 6–8 channels/1 slice) of each layer that showed response in one slice. C, Pooled data of 5 mice. Pre-exposure of the ACC slice with ω-Ctx-GVIA abolished the layer-related difference in the effect of 1S,3R–ACPD and (R)-Baclofen (n = 5 slices/5 mice). The horizontal bars indicate the period of drug application. Error bars represent SEM. D, Reduction index of ω-Ctx-GVIA and neuromodulators in different layers. All drugs showed no statistically significant difference between layers. E, Reduction index of neuromodulators when ω-Ctx-GVIA-insensitive responses (70–90 min in Figure 7C) were normalized as 100%. 1S,3R–ACPD inhibited the ω-Ctx GVIA-insensitive responses more in the deep layer (LII/III: 54.6 ± 7.0%, LV/VI: 77.7 ± 5.0%, P = 0.007). The layer difference was not clear for Baclofen (LII/III: 59.3 ± 2.9%, LV/VI: 75.0 ± 6.3%, P = 0.057), 2-CA (LII/III: 46.3 ± 8.3%, LV/VI: 55.4 ± 6.5%, P = 0.262) and Cch (LII/III: 61.9 ± 1.5%, LV/VI: 64.8 ± 4.3%, P = 0.719). F, Reduction index of each agonist in the superficial layer with (Figure 6F) or without ω-Ctx GVIA (Figure 7E). G, Reduction index of each agonist in the deep layer with (Figure 6F) or without ω-Ctx GVIA (Figure 7E).